Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy

References

• Bonomo Y, Souza JDS, Jackson A, et al. Clinical issues in cannabis use. Br J Clin Pharmacol. 2018 Nov;84(11):2495–2498.
   Google Scholar
• Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;Vol. 382(9904):1564–1574.
   Google Scholar
• Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241–254.
   Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1):1–25.
   Google Scholar
• Devinsky O, Marmanillo A, Hamlin T, et al. Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. Ann Clin Transl Neurol. 2022;9(4):497–505.
   Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.
   Google Scholar
• Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501.
   Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
   Google Scholar
• Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–737.
   Google Scholar
• Mechoulam R, Shvo Y. Hashish—I: the structure of Cannabidiol. Tetrahedron. 1963;19(12):2073–2078.
   Google Scholar
• Grotenhermen F, Müller-Vahl K. Medicinal uses of marijuana and cannabinoids. Crit Rev Plant Sci. 2016;35(5–6):378–405.
   Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(S1):S163–S171.
   Google Scholar
• Hillig KW. Genetic evidence for speciation in Cannabis (Cannabaceae). Genet Resour Crop Evol. 2005;52(2):161–180.
   Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646–1647.
   Google Scholar
• Simiyu DC, Jang JH, Lee OR. Understanding cannabis sativa L.: current status of propagation, use, legalization, and haploid-inducer-mediated genetic engineering. Plants (Basel, Switzerland). 2022. 11(9):1236.
   Google Scholar
• Jin D, Henry P, Shan J, et al. Identification of phenotypic characteristics in three chemotype categories in the genus cannabis. HortScience horts. 2021;56(4):481–490.
   Google Scholar
• ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–548.
   Google Scholar
• Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc. 1971;93(1):217–224.
   Google Scholar
• Citti C, Linciano P, Russo F, et al. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol. Sci Rep. 2019;9(1):20335.
   Google Scholar
• Dufresnes C, Jan C, Bienert F, et al. Broad-scale genetic diversity of cannabis for forensic applications. PLOS ONE. 2017;12(1):e0170522.
   Google Scholar
• Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2004;91(6):966–975.
   Google Scholar
• Welling MT, Shapter T, Rose TJ, et al. A belated green revolution for cannabis: virtual genetic resources to fast-track cultivar development. Front Plant Sci. 2016;7:1113.
   Google Scholar
• Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules [Review]. Front Plant Sci. 2016;7:19.
   Google Scholar
• Pennypacker SD, Cunnane K, Cash MC, et al. Potency and THERAPEUTIC THC and CBD Ratios: U.S. cannabis markets overshoot [Original research]. Front Pharmacol. 2022;13:921493.
   Google Scholar
• Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health [Review]. Front Psychiatry. 2020;11:591979.
   Google Scholar
• ElSohly MA, Mehmedic Z, Foster S, et al. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–619.
   Google Scholar
• Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226.
   Google Scholar
• Pennypacker SD, Romero-Sandoval EA. CBD and THC: do they complement each other like Yin and Yang? Pharmacother J Human Pharmacol Drug Ther. 2020;40(11):1152–1165.
   Google Scholar
• Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–577.
   Google Scholar
• Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142–154.
   Google Scholar
• Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533–543.
   Google Scholar
• Levin DN, Dulberg Z, Chan AW, et al. A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Can J Anaesth. 2017;64(4):385–395.
   Google Scholar
• Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45(5):545–554.
   Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897.
   Google Scholar
• Silvestro S, Mammana S, Cavalli E, et al. Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules. 2019;24(8):1459.
   Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–1359.
   Google Scholar
• Legislatures NCoS. State medical cannabis laws [Internet]. Denver CO: National Conference of State Legislatures. June 2022 Available from: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
   Google Scholar
• Yu B, Chen X, Chen X, et al. Marijuana legalization and historical trends in marijuana use among US residents aged 12–25: results from the 1979–2016 national survey on drug use and health. BMC Public Health. 2020;20(1):156.
   Google Scholar
• Booklet 3 - Drug market trends: opioids, cannabis [Internet]. United Nations Office on Drugs and Crime. June 2022. Available from: https://www.unodc.org/unodc/en/data-and-analysis/wdr-2021_booklet-3.html.
   Google Scholar
• Testai FD, Gorelick PB, Aparicio HJ, et al. Use of marijuana: effect on brain health: a scientific statement from the American heart association. Stroke. 2022;53(4):e176–e187.
   Google Scholar
• SAMHSA releases 2020 national survey on drug use and health. Rockville MD:SAMSHA. October 2021 Available from: https://www.samhsa.gov/newsroom/press-announcements/202110260320.
   Google Scholar
• Kocis PT, Vrana KE. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Med Cannabis Cannabinoids. 2020;3(1):61–73.
   Google Scholar
• Turna J, Syan SK, Frey BN, et al. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res. 2019;43(4):550–563.
   Google Scholar
• Jin D, Dai K, Xie Z, et al. Secondary metabolites profiled in cannabis inflorescences, leaves, stem barks, and roots for medicinal purposes. Sci Rep. 2020;10(1):3309.
   Google Scholar
• Murillo-Rodriguez E. Molecular, biochemical and genetic aspects of cannabinoids. 2015.
   Google Scholar
• Hanuš LO, Meyer SM, Muñoz E, et al. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–1392.
   Google Scholar
• Lelario F, Pascale R, Bianco G, et al. Hemp chemotype definition by cannabinoids characterization Using LC-ESI(+)-LTQ-FTICR MS and infrared multiphoton dissociation. Separations. 2021;8(12):245.
   Google Scholar
• Wang M, Wang Y-H, Avula B, et al. Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. Cannabis Cannabinoid Res. 2016;1(1):262–271.
   Google Scholar
• Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12:777804.
   Google Scholar
• Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56(23):2097–2102.
   Google Scholar
• Leas EC, Nobles AL, Shi Y, et al. Public interest in ∆(8)-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted ∆(9)-Tetrahydrocannabinol (delta-9-THC) use. Int J Drug Policy. 2022;101:103557.
   Google Scholar
• Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180–188.
   Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804.
   Google Scholar
• Cox EJ, Maharao N, Patilea-Vrana G, et al. A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther. 2019;201:25–38.
   Google Scholar
• Ohlsson A, Lindgren J-E, Andersson S, et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986;13(2):77–83
   Google Scholar
• Desrosiers NA, Himes SK, Scheidweiler KB, et al. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60(4):631–643.
   Google Scholar
• Schwope DM, Karschner EL, Gorelick DA, et al. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011;57(10):1406–1414.
   Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–360.
   Google Scholar
• Chayasirisobhon S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2021;25(1):1–3.
   Google Scholar
• Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl). 1981;74(3):208–212.
   Google Scholar
• Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149–156.
   Google Scholar
• Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr. 1990;99:42–62.
   Google Scholar
• Nadulski T, Pragst F, Weinberg G, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27(6):799–810.
   Google Scholar
• Vandrey R, Herrmann ES, Mitchell JM, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017;41(2):83–99.
   Google Scholar
• Taylor L, Gidal B, Blakey G, et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–1067.
   Google Scholar
• Tayo B, Taylor L, Sahebkar F, et al. A phase I, open-label, parallel-group, single-dose trial of the pharmacokinetics, safety, and tolerability of cannabidiol in subjects with mild to severe renal impairment. Clin Pharmacokinet. 2020;59(6):747–755.
   Google Scholar
• Anderson LL, Etchart MG, Bahceci D, et al. Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. Sci Rep. 2021;11(1):14948.
   Google Scholar
• Karschner EL, Schwope DM, Schwilke EW, et al. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012 Oct 1;125(3):313–319.
   Google Scholar
• Millar SA, Stone NL, Yates AS, et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.
   Google Scholar
• Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16(5):276–282.
   Google Scholar
• Guy GW, Robson PJ. A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicine Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther. 2004;3(4):121–152.
   Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199–215.
   Google Scholar
• Toennes SW, Ramaekers JG, Theunissen EL, et al. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol. 2008;32(7):470–477.
   Google Scholar
• Nasrin S, Watson CJW, Perez-Paramo YX, et al. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos. 2021a;49(12):1070–1080.
   Google Scholar
• Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34(3):352–363.
   Google Scholar
• Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica. 1990;20(3):303–320.
   Google Scholar
• Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1(1):90–101.
   Google Scholar
• Levitt DG. Heterogeneity of human adipose blood flow. BMC Clin Pharmacol. 2007;7:1.
   Google Scholar
• Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther. 1990;255(2):624–630.
   Google Scholar
• Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802.
   Google Scholar
• Watanabe K, Yamamoto I, Oguri K, et al. Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice. Drug Metab Dispos. 1981;9(3):261–264.
   Google Scholar
• Calapai F, Cardia L, Sorbara EE, et al. Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceutics. 2020;12(3):265.
   Google Scholar
• Child RB, Tallon MJ. Cannabidiol (CBD) dosing: plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue. Nutrients. 2022;14(10):2101.
   Google Scholar
• Gronewold A, Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int. 2011;210(1–3):e7–e11.
   Google Scholar
• Kudo K, Nagata T, Kimura K, et al. Sensitive determination of delta 9-tetrahydrocannabinol in human tissues by GC-MS. J Anal Toxicol. 1995;19(2):87–90.
   Google Scholar
• Widman M, Agurell S, Ehrnebo M, et al. Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol. 1974;26(11):914–916.
   Google Scholar
• Skopp G, Pötsch L, Mauden M, et al. Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Δ9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci Int. 2002;126(1):17–23.
   Google Scholar
• Wahlqvist M, Nilsson IM, Sandberg F, et al. Binding of δ1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol. 1970;19(9):2579–2582.
   Google Scholar
• Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477–2482.
   Google Scholar
• Bland TM, Haining RL, Tracy TS, et al. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005;70(7):1096–1103.
   Google Scholar
• Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of Δ9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci. 1995;56(23):2089–2095.
   Google Scholar
• Watanabe K, Yamaori S, Funahashi T, et al. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415–1419.
   Google Scholar
• Lemberger L, Silberstein Stephen D, Axelrod J, et al. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science. 1970;170(3964):1320–1322.
   Google Scholar
• Mechoulam R, BenZvi Z, Agurell S, et al. Delta 6-tetrahydrocannabinol-7-oic acid, a urinary delta 6-THC metabolite: isolation and synthesis. Experientia. 1973;29(10):1193–1195.
   Google Scholar
• Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users*. J Anal Toxicol. 1998;22(6):445–454.
   Google Scholar
• Grauwiler SB, Drewe J, Scholer A. Sensitivity and specificity of urinary cannabinoid detection with two immunoassays after controlled oral administration of cannabinoids to humans. Ther Drug Monit. 2008;30(4):530–535.
   Google Scholar
• Gasse A, Vennemann M, Köhler H, et al. Toxicogenetic analysis of Δ9-THC-metabolizing enzymes. Int J Legal Med. 2020;134(6):2095–2103.
   Google Scholar
• Mazur A, Lichti CF, Prather PL, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496–1504.
   Google Scholar
• Halldin MM, Widman M, Vb C, et al. Identification of in vitro metabolites of delta 1-tetrahydrocannabinol formed by human livers. Drug Metab Dispos. 1982;10(4):297–301.
   Google Scholar
• Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005;168:657–690.
   Google Scholar
• Harvey DJ, Martin BR, Paton WD. Identification and measurement of cannabinoids and their in vivo metabolites in liver by gas chromatography–mass spectrometry. Adv Biosci. 1978;22-23:45–62.
   Google Scholar
• Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332–338.
   Google Scholar
• Beers JL, Fu D, Jackson KD. Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metab Dispos. 2021;49(10):882–891.
   Google Scholar
• Williams PL, Moffat AC. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol. 1980;32(7):445–448.
   Google Scholar
• Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg. 2000;55(6):323–333.
   Google Scholar
• Heuberger JA, Guan Z, Oyetayo OO, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet. 2015;54(2):209–219.
   Google Scholar
• Johansson E, Halldin MM, Agurell S, et al. Terminal elimination plasma half-life of Δ1-tetrahydrocannabinol (Δ1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989;37(3):273–277.
   Google Scholar
• Smith-Kielland A, Skuterud B, Mørland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999;23(5):323–332.
   Google Scholar
• Karschner EL, Schwilke EW, Lowe RH, et al. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol. 2009;33(8):469–477.
   Google Scholar
• Taylor L, Crockett J, Tayo B, et al. A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019;59(8):1110–1119.
   Google Scholar
• Perkins D, Butler J, Ong K, et al. A phase 1, randomised, placebo-controlled, dose escalation study to investigate the safety, tolerability and pharmacokinetics of cannabidiol in fed healthy volunteers. Eur J Drug Metab Pharmacokinet. 2020;45(5):575–586.
   Google Scholar
• Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40(3):517–522.
   Google Scholar
• Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623–639.
   Google Scholar
• Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: their signaling and roles in disease [Review]. Front Cell Neurosci. 2017;10. DOI:10.3389/fncel.2016.00294
   Google Scholar
• Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 2002;66(2):101–121.
   Google Scholar
• Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059–1068.
   Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564.
   Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65.
   Google Scholar
• Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16(1):9–29.
   Google Scholar
• Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54–61.
   Google Scholar
• Schatz AR, Lee M, Condie RB, et al. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142(2):278–287.
   Google Scholar
• Simard M, Rakotoarivelo V, Di Marzo V, et al. Expression and functions of the CB2 receptor in human leukocytes [Perspective]. Front Pharmacol. 2022;13:826400.
   Google Scholar
• Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–1936.
   Google Scholar
• Tsou K, Brown S, Sañudo-Peña MC, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393–411.
   Google Scholar
• Bayewitch M, Rhee MH, Avidor-Reiss T, et al. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem. 1996;271(17):9902–9905.
   Google Scholar
• Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48(3):443–450.
   Google Scholar
• Iwamura H, Suzuki H, Ueda Y, et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther. 2001;296(2):420–425.
   Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010;62(4):588.
   Google Scholar
• Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem. 1997;40(20):3228–3233.
   Google Scholar
• Showalter VM, Compton DR, Martin BR, et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996;278(3):989–999.
   Google Scholar
• Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204.
   Google Scholar
• Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–623.
   Google Scholar
• Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805.
   Google Scholar
• Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60(11):2224–2234.
   Google Scholar
• Bakas T, van Nieuwenhuijzen PS, Devenish SO, et al. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA(A) receptors. Pharmacol Res. 2017;119:358–370.
   Google Scholar
• Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092–1101.
   Google Scholar
• Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637–654.
   Google Scholar
• Muller C, Morales P, Reggio PH. Cannabinoid Ligands Targeting TRP Channels. Front Mol Neurosci. 2018;11:487.
   Google Scholar
• Vučković S, Srebro D, Vujović KS, et al. Cannabinoids and pain: new insights from old molecules [Review]. Front Pharmacol. 2018;9. DOI:10.3389/fphar.2018.01259.
   Google Scholar
• Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043.
   Google Scholar
• O’Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol. 2007;152(5):576–582.
   Google Scholar
• Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep. 2020 Nov 23;10(1):20405.
   Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141.
   Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–396.
   Google Scholar
• In vitro drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry [Internet]. Rockville MD:USFood & Drug Administration January 2022 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.
   Google Scholar
• Yamaori S, Kushihara M, Yamamoto I, et al. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 2010;79(11):1691–1698.
   Google Scholar
• Bansal S, Maharao N, Paine MF, et al. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 2020;48(10):1008–1017.
   Google Scholar
• Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome P450 (CYP)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent CYP inhibition in human liver microsomes. Drug Metab Dispos. 2022;50(4):DMD-AR-2021–000734.
   Google Scholar
• Yamaori S, Maeda C, Yamamoto I, et al. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol. 2011a;29(2):117–124.
   Google Scholar
• Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011b;88(15–16):730–736.
   Google Scholar
• Yamaori S, Koeda K, Kushihara M, et al. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet. 2012;27(3):294–300.
   Google Scholar
• Yamaori S, Okamoto Y, Yamamoto I, et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011c;39(11):2049–2056.
   Google Scholar
• Doohan PT, Oldfield LD, Arnold JC, et al. Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization. Aaps j. 2021;23(4):91.
   Google Scholar
• Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
   Google Scholar
• Tolbert D, Bekersky I, Chu HM, et al. Drug-metabolism mechanism: knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions. J Clin Pharmacol. 2016;56(3):365–374.
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–1592.
   Google Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204–e1211.
   Google Scholar
• Morrison G, Crockett J, Blakey G, et al., A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009–1031.
   Google Scholar
• Ridout KK, Young-Wolff KC, Ridout SJ. A change in blood carbamazepine levels associated with cannabis use: implications for clinical practice. J Clin Psychiatry. 2021;82(3). DOI:10.4088/JCP.20cr13777
   Google Scholar
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.
   Google Scholar
• Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. 2019a;39(5):462–471.
   Google Scholar
• Thai C, Tayo B, Critchley D. A phase 1 open-label, fixed-sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279–1289.
   Google Scholar
• Roth MD, Marques-Magallanes JA, Yuan M, et al. Induction and regulation of the carcinogen-metabolizing enzymeCYP1A1 by marijuana smoke andδ 9 -tetrahydrocannabinol. Am J Respir Cell Mol Biol. 2001;24(3):339–344.
   Google Scholar
• Zhang W, Xu G, McLeod HL. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol. 2002;10(4):374–380.
   Google Scholar
• Taketani M, Shii M, Ohura K, et al. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci. 2007;81(11):924–932.
   Google Scholar
• Hatfield MJ, Tsurkan L, Garrett M, et al. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol. 2011;81(1):24–31.
   Google Scholar
• Imai T, Taketani M, Shii M, et al. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 2006 Oct;34(10):1734–1741.
   Google Scholar
• Imai T, Yoshigae Y, Hosokawa M, et al. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration. J Pharmacol Exp Ther. 2003 Dec;307(3):1234–1242.
   Google Scholar
• Wang D, Zou L, Jin Q, et al. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8(5):699–712.
   Google Scholar
• Laizure SC, Herring V, Hu Z, et al. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013;33(2):210–222.
   Google Scholar
• Qian Y, Wang X, Markowitz JS. In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos. 2019b;47(5):465–472.
   Google Scholar
• Qian Y, Markowitz JS. Prediction of carboxylesterase 1 (CES1)-mediated in vivo drug interaction between methylphenidate and cannabinoids using static and physiologically based pharmacokinetic models. Drug Metab Dispos. 2022;50(7):968.
   Google Scholar
• Nasrin S, Watson CJW, Bardhi K, et al., Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites. Drug Metab Dispos. 2021b;49(12):1081–1089.
   Google Scholar
• Meech R, Hu DG, McKinnon RA, et al. The UDP-Glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev. 2019;99(2):1153–1222.
   Google Scholar
• Bushey RT, Lazarus P. Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility. J Pharmacol Exp Ther. 2012;343(3):712–724.
   Google Scholar
• MacKenzie PI, Rogers A, Elliot DJ, et al. The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol. 2011;79(3):472–478.
   Google Scholar
• Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201–1208.
   Google Scholar
• Al Saabi A, Allorge D, Sauvage FL, et al. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos. 2013;41(3):568–574.
   Google Scholar
• Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121–1132.
   Google Scholar
• Patsalos PN, Szaflarski JP, Gidal B, et al. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia. 2020;61(9):1854–1868.
   Google Scholar
• Seo KA, Bae SK, Choi YK, et al. Metabolism of 1’- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos. 2010;38(11):2007–2013.
   Google Scholar
• Abrams DI, Couey P, Shade SB, et al. Cannabinoid–opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844–851.
   Google Scholar
• Takeda S, Kitajima Y, Ishii Y, et al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos. 2006;34(8):1277–1282.
   Google Scholar
• Anderson L, Doohan P, Oldfield L, et al. Citalopram and cannabidiol: in vitro and in vivo evidence of pharmacokinetic interactions relevant to the treatment of anxiety disorders in young people. J Clin Psychopharmacol. 2021;41(5):525–533.
   Google Scholar
• Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377(7):699–700.
   Google Scholar
• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2018;391(10125):1085–1096.
   Google Scholar
• Grayson L, Vines B, Nichol K, et al. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2018;9:10–11.
   Google Scholar
• Damkier P, Lassen D, Christensen MMH, et al. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019;124(1):28–31.
   Google Scholar
• Yamreudeewong W, Wong HK, Brausch LM, et al. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother. 2009;43(7):1347–1353.
   Google Scholar
• Hsu A, Painter NA. Probable interaction between warfarin and inhaled and oral administration of cannabis. J Pharm Pract. 2020;33(6):915–918.
   Google Scholar
• Brown GW, Bellnier TJ, Janda M, et al. Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am Pharm Assoc. 2021;61(1):e57–e60.
   Google Scholar
• Wilson M, Gogulski HY, Cuttler C, et al. Cannabis use moderates the relationship between pain and negative affect in adults with opioid use disorder. Addict Behav. 2018;77:225–231.
   Google Scholar
• Clem SN, Bigand TL, Wilson M. Cannabis use motivations among adults prescribed opioids for pain versus opioid addiction. Pain Manag Nurs. 2020 Feb;21(1):43–47.
   Google Scholar
• Thomas TF, Metaxas ES, Nguyen T, et al. Case report: medical cannabis-warfarin drug-drug interaction. J Cannabis Res. 2022;4(1):6.
   Google Scholar
• Engels FK, de Jong FA, Sparreboom A, et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 2007;12(3):291–300.
   Google Scholar
• Riggs CE Jr., Egorin MJ, Fuks JZ, et al. Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. J Clin Pharmacol. 1981;21(S1):90s–98s.
   Google Scholar
• Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. Aids. 2002;16(4):543–550.
   Google Scholar
• Basit A, Neradugomma NK, Wolford C, et al. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 2020;17(11):4114–4124.
   Google Scholar
• Margaillan G, Rouleau M, Fallon JK, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015;43(4):611.
   Google Scholar
• Yoshida K, Budha N, Jin JY. Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology. Clin Pharmacol Ther. 2017;101(5):597–602.
   Google Scholar
• Huang SM, Abernethy DR, Wang Y, et al. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013;102(9):2912–2923.
   Google Scholar
• Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration’s office of clinical pharmacology. J Pharm Sci. 2019;108(1):21–25
   Google Scholar
• Jamei M. Recent advances in development and application of Physiologically-Based Pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Current Pharmacol Rep. 2016;2(3):161–169.
   Google Scholar